

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Wei et al.  
U.S. Serial No. : 10/650,365  
Confirmation No. : 7677  
Filed : August 28, 2003  
Examiner : Jegatheesan Seharaseyon  
Art Unit : 1647  
For : RECOMBINANT SUPER-COMPOUND INTERFERON

Law Offices of Albert Wai-Kit Chan, LLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357

July 3, 2007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir/Madam:

SUPPLEMENTAL RESPONSE TO AUGUST 23, 2005 OFFICE ACTION

This Amendment is being submitted as a Supplemental Response to the August 23, 2005 Office Action which was issued by the United States Patent and Trademark Office (USPTO) in connection with the above-identified application.

Priority

The Examiner acknowledged Applicants' claim for foreign priority based on an application filed in China on February 28, 2001. However, the Examiner also noted that Applicants did not file a

Applicant(s) : Wei et al.  
U.S. Serial No.: 10/650,365  
Filed : August 28, 2003  
Page : 2

translated copy of the Application No. CHINA 01104367.9. Therefore the priority is set forth as the filing date of the instant application. Consequently, Applicants respectfully submit **Exhibit 1** (16 pages), which is the European counterpart of Applicant's International application referring to the same invention. It serves as the English translation of PCT/CN02/00128 and claims priority to Chinese Patent CN 01104367.9, filed on February 28, 2001.

If a telephone interview would be of assistance in advancing the prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided below. If any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan

Albert Wai-Kit Chan  
Registration No. 36,479  
Attorney for Applicant(s)  
Law Offices of  
Albert Wai-Kit Chan, PLLC  
World Plaza, Suite 604  
141-07 20<sup>th</sup> Avenue  
Whitestone, New York 11357  
Tel: (718) 799-1000  
Fax: (718) 357-8615  
E-mail: chank@kitchanlaw.com

# EXHIBIT 1

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 371 373 A1

(12)

# EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:  
17.12.2003 Bulletin 2003/51

(51) Int Cl.7: **A61K 38/21**, A61P 1/16,  
A61P 31/12, C12N 15/20,  
C12N 15/63, C12N 15/70

(21) Application number: 02702211.0

(22) Date of filing: 28.02.2002

(86) International application number:  
PCT/CN02/00128

(87) International publication number:  
WO 02/080958 (17.10.2002 Gazette 2002/42)

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU**  
**MC NL PT SE TR**  
Designated Extension States:  
**AL LT LV MK RO SI**

(30) Priority: 28.02.2001 CN 01104367

(71) Applicant: Sichuan Biotechnology Research  
Center  
Chengdu City, Sichuan 610017 (CN)

(72) Inventors:  
• **WEI, Guangwen**  
Chengdu City, Sichuan 610017 (CN)  
• **GUO, Rongbing**  
Chengdu City, Sichuan 610017 (CN)  
• **ZHANG, Renhual**  
Chengdu City, Sichuan 610017 (CN)

(74) Representative: Capasso, Olga et al  
de Simone & Partners  
Via Vincenzo Bellini, 20  
00198 Roma (IT)

## (54) RECOMBINATION SUPER COMPOUND INTERFERON USED AS HEPATITIS B SURFACE ANTIGEN AND E ANTIGEN INHIBITOR

(57) The present invention relates to the use of recombination super compound interferon (rSIFN-co) as

hepatitis B surface antigen and e antigen inhibitor, in which the dimensional structure of said interferon protein has been changed.

Figure 1

```

5'      11      21      31      41      51
+1 N C D L P Q T H S L G N R R A L I L L A
1 ATGCTGATT TACCTCAGAC TONTTCTCTT CGTAACCGTC GCGCTCTGAT TCTGCTGGCA
TACACACTAA ATGGAGTTTG ASTRAGAGRA CATTGGGCGS GCGAGAGCTA AGACGACCTT

5'      71      81      91      1      11
+1 Q N R R X Y S F P S C L K D R R D P G F P
61 CAGATGCGTC GTATTTCGCC GTTTAGCTGC CTGAAAGACC GTCACGACTT GCGCTTCCG
GCTACGCGAG CATAAAGGGG CAAATCGAGC GACTTCTGCG CAGTCTGAA GCGGAAGGC

5'      31      41      51      61      71
+1 Q E E F D G M O P Q K A Q A I S V L H E
121 CAGAGAGAT TCGATGCGAA CCAATTCGAG AAGCTCAGG CATCTCTGT ACTGCAGAA
GTTCTCTCA AGCTACCGTT GGTAAAGGTC TTTCGAGTCC GTTAGAGACA TGACGTGCTT

5'      91      1      11      21      31
+1 M I Q Q T F N L F S T K D S S A A W D E
181 ATGATCCGAC AGACCTTCAA CHTGTTTCC ACTAAGACA GCTCTGCTGC TTGCGAGCA
TACTAGGTTG TCTGGAAGTT GGACAAAGG TGATTCTGT CAGACGAGG AACCTGCTT

5'      51      61      71      81      91
+1 S L L E K F Y T E L Y Q Q L N D L E A C
241 AGCTTGTGCG AGAAGTTCTA CACTGAACTG TATCGAGAGC TGACGACCT GAGACGATC
TCGACGAGC TOTTCAAGAT GTGACTTGAC ATATGCTGCG ACTTCTGGA CTTTCTGAGC

5'      11      21      31      41      51
+1 V I Q E V G V E S T P L M N V D S I L A
301 GTAATCCAGG AAGTTGGTGT AGRAGAGACT CCGCTGATGA AGTCTGACTC TATCTGGCA
CATAGGTCG TCGACGACA TCTCTCTGA GCGCACTACT TCGACTGAG ATAGACCGT

```

EP 1 371 373 A1

## Description

## FIELD OF THE INVENTION

[0001] This invention is related to a recombinant super-compound interferon (rSIFN-co) with changed dimensional structure. The characteristic of rSIFN-co in this invention is that it cannot only inhibit DNA (deoxyribonucleic acid) duplication of the hepatitis B virus but also the secretion of HBsAg and HBeAg.

## BACKGROUND OF THE INVENTION

[0002] rSIFN-co is a new interferon molecule constructed with the most popular conservative amino acid found in natural human  $\alpha$ -IFN subtypes using genetic engineering methods. United States Patent Nos. 4,695,623 and 4,897,471 have described it. rSIFN-co had been proved to have broad-spectrum IFN activity and virus- and tumor-inhibition and natural killer cell activity. United States Patent No. 5,372,808 by Amgen, Inc. addresses treatment rSIFN-co. Chinese Patent No. 97193506.8 by Amgen, Inc. addresses re-treatment of rSIFN-co on hepatitis C. Chinese Patent No. 98114663.5 by Shenzhen Jilusheng Bio-engineering Ltd. addresses treatment of rSIFN-co on hepatitis B and hepatitis C.

[0003] The United States Food and Medicine Administration (FDA) authorized Amgen Ltd. to produce rSIFN-co with *E. Coli* for clinical hepatitis C treatment at the end of 1997.

[0004] Hepatitis B patients can be identified when detecting HBsAg and the HBeAg.  $\alpha$ -IFN is commonly used in clinics to treat hepatitis B. IFN binds superficial cell membrane receptors, inhibiting DNA and RNA (ribonucleic acid) duplication, including inducing some enzymes to prevent duplication of the virus in hepatitis-infected cells. All IFNs can inhibit only the DNA duplication of viruses, not the e and s antigen.

## DETAILED DESCRIPTION OF THE INVENTION

## Invention Component

[0005] It was surprising to find that rSIFN-co, the dimensional structure of which has been changed, is not only a preparation to inhibit the DNA duplication of hepatitis B, but to inhibit the secretion of HBsAg and HBeAg.

[0006] The objective of this invention is to offer a preparation of rSIFN-co to inhibit the DNA duplication of hepatitis B viruses and the secretion of HBeAg and HBsAg of hepatitis B and decrease them to normal levels.

[0007] *Results of this invention:* The production of rSIFN-co with recombinant techniques. On the condition of fixed amino acid sequence, the IFN DNA was redesigned according to the *E. Coli* codon usage and then the rSIFN-co gene was artificially synthesized.

[0008] rSIFN-co cDNA was cloned into the high-expression vector of *E. Coli* by DNA recombinant techniques, and a high expression of rSIFN-co was gained by using of induce/activate-mechanism of L-arabinose to activate the transcription of  $P_{BAD}$  promoter.

[0009] Compared with usual thermo-induction, pH induction and IPTG induction systems of genetic engineering, arabinose induction/activation system has some advantages: (1) Common systems relieve promoter function by creating a "derepression" pattern. Promoters then induce downstream gene expression. So temperature and pH change and the addition of IPTG cannot activate promoters directly. In the system disclosed herein, L-arabinose not only deactivates and represses but also activates the transcription of  $P_{BAD}$  promoter which induce a high expression of rSIFN-co. Therefore, the arabinose induction/activation system is a more effective expression system. (2) The relation between Exogenous and L-arabinose dosage is linearity. This means the concentration of arabinose can be changed to adjust the expression level of the exogenous gene. Therefore, it is easier to control the exogenous gene expression level in *E.coli* by arabinose than by changing temperature and pH value. This characteristic is significant for the formation of inclusion bodies. (3) L-arabinose is resourceful cheap and safe, which, on the contrary, are the disadvantages of other inducers such as IPTG.

[0010] This invention creates an effective and resistant rSIFN-co-expressing *E. Coli* engineering strain with an L-arabinose induction/activation system. The strain is cultivated and fermented under suitable conditions to harvest the bacterial bodies. Inclusion bodies are then purified after destroying bacteria and washing repeatedly. The end result, mass of high-purity, dimensional-structure-changed rSIFN-co protein for this invention and for clinical treatment, was gained from denaturation and renaturation of inclusion bodies and a series of purification steps.

[0011] The following are some rSIFN-co preparations: tablets, capsules, oral liquids, pastes, injections, sprays, suppositories, and solutions. Injections are recommended. It is common to subcutaneously inject or vein-inject the medicine. The medicine carrier could be any acceptance medicine carrier, including carbohydrate, cellulose, adhesive, collapse, emollient, filling, add-dissolve agent, amortization, preservative, add-thick agent, matching, etc.

## DETAILED DESCRIPTION OF THE FIGURE

[0012] Figure 1. DNA coding sequence and deduced amino acid sequence of rSIFN-co

## EXPERIMENTAL DETAILS

## Embodiment experience:

[0013] The invention disclosed herein also experimentally verifies that the dimensional-structure-changed rSIFN-co can inhibit HBV-DNA duplication and secretion of HBsAg and HBeAg.

## Materials

[0014] Solvent and Dispensing Method: Add 1ml saline into each vial, dissolve, and mix with MEM culture medium at different concentrations. Mix on the spot.

[0015] Control drugs: IFN- $\alpha$ 2b (Intron A) as lyophilized, purchased from Schering Plough.  $3 \times 10^6$ U each, mix to  $3 \times 10^6$ U/ml with culture medium; INFERGEN (liquid solution), purchased from Amgen, 9 $\mu$ g, 0.3ml each, equal to  $9 \times 10^6$ U, and mix with  $9 \times 10^6$ U/ml culture medium preserve at 4°C; 2.2.15 cell: 2.2.15 cell line of hepatoma (Hep G2) cloned and transfected by HBV DNA, constructed by Mount Sinai Medical Center.

[0016] Reagent: MEM powder, Gibco American Ltd. cattle fetal blood serum, HycloneLab American Ltd. G-418(Geneticin); MEM dispensing, Gibco American Ltd.; L-Glutamyl, imported and packaged by JING KE Chemical Ltd.; HBsAg and HBeAg solid-phase radioimmunoassay box, Northward Reagent Institute of Chinese Isotope Ltd.; Biogranctina, Northern China Medicine; And Lipofectin, Gibco American Ltd.

[0017] Experimental goods and equipment: culture bottle, Denmark Tuncion™; 24-well and 96-well culture board, Corning American Ltd.; Carbon Dioxide hatching box, Shel-Lab American Ltd.; MEM culture medium 100ml: 10% cattle fetal blood serum, 3% Glutamyl1%, G418 380 $\mu$ g/ml, biogranctina50U/ml.

## Method:

[0018] 2.2.15 cell culture: Added 0.25% pancreatic enzyme into culture box with full of 2.2.15 cell, digest at 37°C for 3 minutes, and add culture medium to stop digest and disturb it to disperse the cells, reproduce with ratio of 1:3. They will reach full growth in 10 days.

[0019] Medicine toxicity test: In this test, set groups of different medicine concentrations and a control group in which cell is not acted on with medicine. Digest cell, and dispense to a 100,000 cell/ml solution. Inoculate to 96-well culture board, 200 $\mu$ l each well, culture at 37°C for 24h with 5% CO<sub>2</sub>. Test when simple cell layer grows.

[0020] Dispense rSIFN-co to  $1.8 \times 10^7$ U/ml solution then prepare a series of solutions diluted at two-fold gradients. Add into 96-well culture board, 3 wells per concentration. Change the solution every 4 days. Test cytopathic effect by microscope after 8 days. Fully destroy as 4, 75% as 3, 50% as 2, 25% as 1, zero as 0. Calculate average cell lesion and inhibition rate of different concentrations. Calculate TC50 and TC0 according to the Reed Muench method.

$$TC50 = \text{Antilog} \left( B + \frac{50-B}{A-B} \times C \right)$$

A=log >50 % medicine concentration, B=log <50 % medicine concentration, C=log dilution power

[0021] Inhibition test for HBeAg and HBsAg: Separate into positive and negative HBeAg and HBsAg contrast groups, cell contrast group and medicine concentration groups. Inoculate 700,000 cells/ml of 2.2.15 cell into 6-well culture board, 3 ml each well, culture at 37°C for 24h with 5% CO<sub>2</sub>, then prepare 5 gradiently diluted solutions with 3-fold as the grade (Prepare 5 solutions, each with a different protein concentration. The concentration of Solution 2 is 3 times lower than that of Solution 1, the concentration of Solution 3 is 3 times lower than that of Solution 2, etc.)  $4.5 \times 10^6$ U/ml,  $1.5 \times 10^6$ U/ml,  $0.5 \times 10^6$ U/ml,  $0.17 \times 10^6$ U/ml, and  $0.056 \times 10^6$ U/ml, 1 well per concentration, culture at 37°C for 24h with 5% CO<sub>2</sub>. Change solutions every 4 days using the same solution. Collect all culture medium on the 8<sup>th</sup> day. Preserve at -20°C Repeat test 3 times to estimate HBsAg and HBeAg with solid-phase radioimmunoassay box (Northward Reagent Institute of Chinese Isotope Ltd.). Estimate cpm value of each well with a  $\gamma$ -accounting machine.

[0022] Medicinal effects calculation: Calculate cpm mean value of contrast groups and different-concentration groups and their standard deviation, P/N value such as inhibition rate, IC50 and SI.

$$1) \text{ Antigen inhibition rate (\%)} = \frac{A-B}{A} \times 100$$

- [0023] A = cpm of control group; B = cpm of test group;  
2) Counting the half-efficiency concentration of the medicine

$$\text{Antigen inhibition IC50} = \text{Antilog} \left( B + \frac{50-B}{A-B} \times C \right)$$

A=log>50% medicine concentration, B=log<50 % medicine concentration, C=log dilution power

- 3) SI of interspace-conformation changed rSIFN-co effect on HBsAg and HBeAg in 2.2.15 cell culture:

$$SI = \frac{TC50}{IC50}$$

- 4) Estimate the differences in cpm of each dilution degree from the control group using student t test

[0024] Southern blot: (1) HBV-DNA extract in 2.2.15 cell: Culture cell 8 days. Exsuction culture medium (Separate cells from culture medium by means of draining the culture medium.). Add lysis buffer to break cells, then extract 2 times with a mixture of phenol, chloroform and isoamyl alcohol (1:1:1), 10,000g centrifuge. Collect the supernatant adding anhydrous alcohol to deposit nucleic acid. Vacuum draw, redissolve into 20μl TE buffer. (2) Electrophoresis: Add 6X DNA loading buffer, electrophoresis on 1.5% agarose gel, 1V/cm, at fixed pressure for 14-18h. (3) Denaturation and hybridization: respectively dip gel into HCl, denaturation buffer and neutralization buffer. (4) Transmembrane: Make an orderly transfer of DNA to Hybond-N membrane. Bake, hybridize and expose with dot blot hybridization. Scan and analyze relative density with gel-pro software. Calculate inhibition rate and IC50.

#### Results

[0025] Results from Tables 1, 2 and 3 show: After maximum innocuous concentration exponent culturing for 8 days with 2.2.15 cell, the maxima is  $9.0 \pm 0 \times 10^6$  IU/ml and the average inhibition rate of maximum innocuous concentration rSIFN-co to HBeAg is  $46.0 \pm 5.25\%$  ( $P < 0.001$ ), IC50 is  $4.54 \pm 1.32 \times 10^6$  IU/ml, SI is 3.96; rate to HBsAg is  $44.8 \pm 6.6\%$ , IC50 is  $6.48 \pm 0.42 \times 10^6$  IU/ml, SI is 2.77. This shows that rSIFN-co can significantly inhibit the activity of HBeAg and HBsAg, but that the IFN of the contrast group and INFERGEN cannot. It has also been proved in clinic that rSIFN-co can decrease HBeAg and HBsAg or return them to normal levels.

[0026] The following are some examples for the preparation of rSIFN-co:

#### Example 1: Preparation of lyophilized Injection

##### [0027]

- a) rSIFN-co  $3 \times 10^6$  IU
- b) citric acid 0.2 mg
- c) dibasic sodium phosphate 2.5 mg
- d) NaCl 4.0 mg
- e) dextran 20 mg
- f) Polyoxyethylene anhydrosorbitol monooleo-acids ester 0.1 ml
- g) Inject water to a level of 1.0 ml

[0028] Preparation technique: Weigh materials according to recipe. Dissolve with sterile and pyrogen-free water. Filter through 0.22μm membrane to de-bacterialize, preserve at 6-10°C. Fill in vials after affirming it is sterile and pyrogen-free. Add 1.0 ml solution to each bottle, and lyophilize in freeze dryer.

#### Example 2: Preparation of liquid Injection

##### [0029]

- a) rSIFN-co  $3 \times 10^6$  IU
- b) citric acid 0.2 mg
- c) dibasic sodium phosphate 2.5 mg
- d) NaCl 4.0 mg
- e) dextran 20 mg
- f) Polyoxyethylene anhydrosorbitol monooleo-acids ester 0.1 ml

**EP 1 371 373 A1**

g) inject water to a level of 1.0 ml

**[0030]** Preparation technique: Weigh materials according to recipe. Dissolve with sterile and pyrogen-free water. Filter through 0.22µm membrane to de-bacterialize, preserve at 6-10°C. Fill in airtight vial after affirming it is sterile and non-pyrogen at 1.0 ml per vial. Store end product at 2-10°C, and protect from light.

10

15

20

25

30

35

40

45

50

55

Table 1: Results of inhibition rate of rSIFN-co to HBSAg and HBsAg  
First batch: (rSIFN-co)

Inhibition effect to HBsAg										
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate
				First well	Second well	Third well				
900	9026	8976	10476	0.436227	0.43935	0.345659	0.407079	0.945909	0.592321	0.614693546
300	9636	12082	10098	0.3993754	0.245347	0.369269	0.337997	0.5388299	1.254924	0.300332321
100	9822	16002	12800	0.386508	0.0803	0.2005	0.195836	0.209833	2.059088	0.08867108
33.33333	15770	19306	18924	0.014991	0	0	0.004997	0.0049969	3.054091	0.001633453
11.1111	19172	22270	18934	0	0	0	0	0	4.054091	0
Control	Cell	16010	Blank	0	0	0	Dilution	3	IC50	692.7446016

Inhibition effect to HBsAg										
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate
				First well	Second well	Third well				
900	7706	7240	7114	0.342155	0.381936	0.392693	0.372261	0.922258	0.627739	0.595006426
300	8956	7778	9476	0.2439816	0.336008	0.191053	0.257014	0.5499972	1.370724	0.286349225
100	10818	10720	10330	0.07649	0.084856	0.118149	0.093165	0.292983	2.27756	0.113977019
33.33333	10744	11114	10570	0.082807	0.051221	0.097661	0.07723	0.1998179	3.20033	0.058767408
11.1111	10672	9352	10810	0.08953	0.201639	0.077173	0.122589	0.122588	4.077742	0.02918541
Control	Cell	11714	Blank	0	0	0	Dilution	3	IC50	641.7736749

Second batch: (ZSIFW-co)

Inhibition effect to HBeAg									
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation
				First well	Second well	Third well			
900	7818	8516	9350	0.554378	0.514592	0.467054	0.512008	1.371181	0.487992
300	10344	10628	9160	0.4103967	0.394209	0.477884	0.427497	0.8591731	1.060496
100	12296	14228	13262	0.299134	0.18901	0.244072	0.244072	0.4316522	1.816423
33.33333	15364	17414	16188	0.124259	0.00741	0.77291	0.069653	0.1876045	2.74677
11.11111	17386	13632	15406	0.009006	0.222982	0.121865	0.117951	0.117951	3.628819
Control	Cell	16962		Blank	0		Dilution	3	IC50
									365.9357846
Inhibition effect to HBsAg									
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation
				First well	Second well	Third well			
900	5784	6198	5792	0.498265	0.462353	0.497571	0.486063	0.893477	0.513937
300	7150	8534	8318	0.379771	0.259715	0.278452	0.30598	0.4074138	1.207957
100	9830	11212	10210	0.147284	0.027412	0.11433	0.096345	0.101434	2.111612
33.33333	13942	22368	13478	0	0	0	0	0.0050891	3.111612
11.11111	12418	11634	11352	0	0	0.015267	0.005089	0.005089	4.106523
Control	Cell			Blank	0		Dilution	3	IC50
									611.0919568

Third batch: (xSIFN-co)

Inhibition effect to HBeAg										
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate
				First well	Second well	Third well				
900	9702	9614	8110	0.428016	0.433204	0.521872	0.461031	1.316983	0.538969	0.709599543
300	8914	10032	8870	0.4744723	0.40856	0.477066	0.4533366	0.8559525	1.085603	0.440859127
100	16312	12688	13934	0.038321	0.251975	0.178517	0.156271	0.402586	1.929332	0.172641621
33.33333	15080	12814	13288	0.110954	0.244547	0.216602	0.190701	0.2463153	2.738631	0.082519156
11.11111	21928	15366	15728	0	0.094093	0.072751	0.0055615	0.055615	3.683017	0.014875633
Control	Cell	17544	Blank	Blank	0		Dilution	3	IC50	382.0496935
Inhibition effect to HBsAg										
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate
				First well	Second well	Third well				
900	5616	6228	5346	0.496864	0.442035	0.531054	0.486651	0.763125	0.513349	0.597838293
300	8542	8590	7096	0.234725	0.230425	0.364272	0.276474	0.2764738	1.236875	0.182690031
100	11420	11360	11394	0	0	0	0	0	2.236875	0
33.33333	12656	11582	13110	0	0	0	0	0		0
11.11111	13142	12356	13342	0	0	0	0	0	4.236875	0
Control	Cell	11529	Blank	Blank	0		Dilution	3	IC50	694.7027149

HBeAg: Average IC50: 450.2434 SD: 132.115479

HBsAg: Average IC50: 649.1894 SD: 42.29580

Table 2: Results of inhibition rate of Intron A (IFN- $\alpha$ 2b) to HBsAg and HBeAg

Inhibition effect to HBeAg									
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation
				First well	Second well	Third well			
300	14918	11724	9950	0	0.029711	0.176529	0.068747	0.068747	0.931253
100	14868	16890	15182	0	0	0	0	0	1.931253
33.33333	16760	21716	16400	0	0	0	0	0	2.931253
11.11111	20854	15042	16168	0	0	0	0	0	3.931253
3.703704	12083	12083	12083	0	0	0	0	0	4.931253
Control	Cell	17544		Blank	0		Dilution	3	IC50
									FALSE
Inhibition effect to HBsAg									
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation
				First well	Second well	Third well			
300	9226	8196	9658	0.152489	0.247106	0.531054	0.1708	0.189295	0.8292
100	10946	10340	10828	0	0.050156	0.364272	0.018495	0.0184947	1.810705
33.33333	12250	12980	13934	0	0	0	0	0	2.810705
11.11111	12634	12342	12000	0	0	0	0	0	3.810705
3.703704	10886	10886	10886	0	0	0	0	0	4.810705
Control	Cell	10886		Blank	0		Dilution	3	IC50
									FALSE

Table 3: Results of inhibition rate of Inergen to HBSAg and HBeAg  
First batch: (Inergen)

Inhibition effect to HBeAg									
Concentration ( $\times 10^4$ IU/ml)	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate		
	First well	Second well	Third well						
900	14172	12156	17306	0.091655	0.220869	0	0.104175	0.306157	0.895825
300	13390	12288	16252	0.1417767	0.212409	0	0.118062	0.3019827	1.777764
100	14364	18834	14194	0.079349	0	0.090245	0.056531	0.083921	2.721232
33.33333	15722	16034	16340	0	0	0	0	0.0273897	3.721232
11.11111	17504	17652	14320	0	0	0.082169	0.02739	0.02739	4.693843
Control	Cell	15602		Blank	0		Dilution	3	IC50
									FALSE
Inhibition effect to HBSAg									
Concentration ( $\times 10^4$ IU/ml)	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation	Accumulated inhibition rate		
	First well	Second well	Third well						
900	12080	11692	12234	0	0.01275	0	0.00425	0.025163	0.99575
300	12840	11484	12350	0	0.030313	0	0.010104	0.0209125	1.985646
100	12894	14696	15086	0	0	0	0	0.010808	2.985646
33.33333	15032	12928	13020	0	0	0	0	0.0108081	3.985646
11.11111	11794	11984	11508	0.004137	0	0.028287	0.010808	0.010808	4.974837
Control	Cell	11843		Blank	0		Dilution	3	IC50
									FALSE

## Second batch: (Infergen)

Inhibition effect to HBeAg									
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation
				First well	Second well	Third well			
900	6278	6376	6408	0.200051	0.187564	0.183486	0.190367	0.274635	0.809633
300	7692	9092	6394	0.0198777	0	0.18527	0.068383	0.0842678	1.74125
100	8960	7474	8190	0	0.047655	0	0.015885	0.015885	2.725365
33.33333	8530	8144	9682	0	0	0	0	0	3.725365
11.11111	7848	7848	7848	0	0	0	0	0	4.725365
Control	Cell	7848		Blank	0		Dilution	3	IC50
									FALSE
Inhibition effect to HBeAg									
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation	1- Accumulation
				First well	Second well	Third well			
900	12364	12268	12274	0.036171	0.043655	0.043187	0.041004	0.140162	0.958996
300	13590	12708	13716	0.0965076	0.009395	0	0.035287	0.0991581	1.923709
100	12448	13468	13982	0.029623	0	0	0.009874	0.063871	2.913834
33.33333	12616	11346	12444	0.016526	0.115529	0.029935	0.053996	0.0539965	3.859838
11.11111	12828	12828	12828	0	0	0	0	0	4.859838
Control	Cell	12828		Blank	0		Dilution	3	IC50
									FALSE

Third batch: (Infergen)

Inhibition effect to HBeAg										
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation n	1- Accumulation n	Accumulate d inhibition rate
				First well	Second well	Third well				
900	7240	5642	6158	0.064599	0.1418	0.20439	0.136951	0.217399	0.863049	0.20131173
300	11072	8786	6902	0	0	0.10826	0.03609	0.0804479	1.82696	0.04217656
100	7015	9726	7552	0.09354	0	0.02428	0.039276	0.044358	2.787683	0.01566301
33.33333	7622	8866	8676	0.015245	0	0	0.005082	0.0050818	3.782601	0.00134167
11.11111	7740	7740	7740	0	0	0	0	0	4.782601	0
Control	Cell	7740		Blank	0		Dilution	3	IC50	FALSE
Inhibition effect to HBeAg										
Concentration ( $\times 10^4$ IU/ml)	First well	Second well	Third well	Inhibition rate			Average inhibition rate	Accumulation n	1- Accumulation n	Accumulate d inhibition rate
				First well	Second well	Third well				
900	11048	11856	11902	0.04775	0	0	0.015917	0.015917	0.984083	0.01591679
300	13454	12896	11798	0	0	0	0	0	1.984083	0
100	12846	13160	12546	0	0	0	0	0	2.984083	0
33.33333	12680	12458	12360	0	0	0	0	0	3.984083	0
11.11111	11602	11602	11602	0	0	0	0	0	4.984083	0
Control	Cell	11602		Blank	0		Dilution	3	IC50	FALSE

HBeAg: Average IC50: 0 SD: 0

HBsAg: Average IC50: 0 SD: 0

## Claims

1. A recombinant super-compound interferon (rSIFN-co) with changed 3-dimensional structure and improved efficacy which can inhibit the DNA duplication and secretion of HBsAg and HBeAg of HBV.
2. The interferon of claim 1, wherein the 3-dimensional change was the result of changes of its production techniques, and efficacy gains not seen in interferon described in U.S. Patent Nos. 4,695,623 and 4,897,471.
3. A super-compound interferon of claim 1 or claim 2, wherein it has its unique secondary and tertiary structure which elicit its special efficacies.
4. A super-compound interferon of claim 1 or claim 2, produced by a highly efficient express system which is constructed with a special promoter.
5. The super-compound Interferon of claim 4, wherein the promoter is P<sub>BAD</sub>.
6. The super-compound interferon of claim 4, wherein its gene is artificially synthesized cDNA, adjusted according to codon preference of *E. Coli*.
7. A process for production of recombinant super-compound interferon recited in claim 1 or 2.
8. The process for production of claim 7, comprising extraction of super-compound interferon from fermentation broth, collection of inclusion body, denaturation and renaturation of the harvested protein.
9. The process of claim 7, wherein the process maintains the high efficacy even when the super-compound interferon is used with an agent and in a particular concentration.
10. The process of claim 7, comprising separation and purification of the super-compound interferon.
11. The process of claim 7, comprising lyophilization of purified super-compound interferon.
12. The process of claim 7, comprising production of liquid injection of super-compound interferon.
13. Uses of super-compound interferon in preparing medicines for inhibition of HBV-DNA, HBsAg and HBeAg, wherein the virus diseases comprising hepatitis A, hepatitis B, hepatitis C, other types of hepatitis, infections of viruses such as: Epstein-Barr virus, HIV, herpes viruses (Epstein-Barr virus, Cytomegalovirus, herpes simplex viruses), papovaviruses, poxviruses, picornaviruses, adenoviruses, rhinoviruses, human T cell leukaemia viruses I, or human T cell leukaemia viruses II.
14. Uses of claim 1 and 2, wherein the super-compound interferon selected for Interferon is  $\alpha$ ,  $\beta$ ,  $\gamma$  such as, IFN-1a, IFN-2b or other mutants.
15. Uses of claim 13, wherein super-compound interferon was administered via oral, vein injection, muscle injection, subcutaneous injection, nasal, or mucosal administration.
16. Uses of claim 13, wherein super-compound interferon was administered following the protocol as follows: injection 8  $\mu$ g or 15  $\mu$ g per day, 3 times a week, total 24 weeks.

Figure 1

```

5'          11          21          31          41          51
+1 M C D L P Q T H S L G N R R A L I L L A
1 ATGTGTGATT TACCTCAAAC TCATTCTCTT GGTAACCGTC GCGCTCTGAT TCTGCTGGCA
TACACACTAA ATGGAGTTTG AGTAAGAGAA CCATTGGCAG CGCGAGACTA AGACGACCGT

5'          71          81          91          1          11
+1 Q M R R I S P F S C L K D R H D F G F P
61 CAGATGCGTC GTATTTCCCC GTTAGCTGC CTGAAAGACC GTCACGACTT CGGCTTTCCG
GTCTACGCAG CATAAAGGGG CAAATCGACG GACTTTCTGG CAGTGCTGAA GCCGAAAGGC

5'          31          41          51          61          71
+1 Q E E F D G N Q F Q K A Q A I S V L H E
121 CAAGAAGAGT TCGATGGCAA CCAATTCCAG AAAGCTCAGG CAATCTCTGT ACTGCACGAA
GTCTTCTCA AGCTACCGTT GGTTAAGTC TTTGAGTCC GTTAGAGACA TGACGTGCTT

5'          91          1          11          21          31
+1 M I Q Q T F N L F S T K D S S A A W D E
181 ATGATCCAAC AGACCTTCAA CCTGTTTTCC ACTAAAGACA GCTCTGCTGC TTGGGACGAA
TACTAGGTTG TCTGGAAGTT GGACAAAAGG TGATTTCTGT CGAGACGACG AACCTTGCTT

5'          51          61          71          81          91
+1 S L L E K F Y T E L Y Q Q L N D L E A C
241 AGCTTGCTGG AGAAGTTCTA CACTGAACTG TATCAGCAGC TGAACGACCT GGAAGCATGC
TCGAACGACC TCTTCAAGAT GTGACTTGAC ATAGTCGTG ACTTGCTGGA CCTTCGTACG

5'          11          21          31          41          51
+1 V I Q E V G V E E T P L M N V D S I L A
301 GTAATCCAGG AAGTTGGTGT AGAAGAGACT CCGCTGATGA ACGTCGACTC TATTCTGGCA
CATTAGGTCC TTCAACCACA TCTTCTCTGA GCGGACTACT TGCAGCTGAG ATAAGACCGT

```

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CN02/00128

A. CLASSIFICATION OF SUBJECT MATTER		
IPC: A61K38/21, A61P1/16, A61P31/12, C12N15/20, C12N15/63, C12N15/70 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC: A61K38/21, A61P1/16, A61P31/12, C12N15/20, C12N15/63, C12N15/70		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Chinese Patents, Chinese Scientific and Technical Journals		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPOQUE, BA, MEDLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO9321229(AMGEN INC et al), 28. Oct. 1993 see abstract	1-16
A	WO8304053(AMGEN INC et al), 24. Nov. 1983 see abstract	1-16
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim (S) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&amp;" document member of the same patent family</p>		
Date of the actual completion of the international search 23. July. 2002(23. 07. 02)		Date of mailing of the international search report 08 AUG 2002 (08. 08. 02)
Name and mailing address of the ISA/CN 6 Xitucheng Rd., Jinan Bridge, Haidian District, 100088 Beijing, China Facsimile No. 86-10-62019451		Authorized officer SUN, Guangxiu Telephone No. 86-10-62093884

Form PCT/ISA/210 (second sheet) (July 1998)

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/CN02/00128

Patent document cited in search report	Publication date	Patent family members	Publication date
WO 9321229	1993-10-28	US5372808	1994-12-13
		EP0641359	1995-03-08
		CN1081909	1994-02-16
		JP7505894T	1995-06-29
WO 8304053	1983-11-24	EP0108128	1984-05-16
		JP59501097T	1984-06-28
		US4897471	1990-01-30

Form PCT/ISA/210 (patent family annex) (July 1998)